Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of ceritinib in preparation of medicine for treating thyroid-associated ophthalmopathy

A technology of ceritinib and thyroid, applied in the field of medicine

Active Publication Date: 2021-08-13
SHANGHAI FIRST PEOPLES HOSPITAL
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] The present invention aims at the problem that the existing TAO has no FDA-approved small-molecule drug for inhibiting fat hyperplasia, and provides ceritinib in the preparation of a drug for treating thyroid-related eye disease application in

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of ceritinib in preparation of medicine for treating thyroid-associated ophthalmopathy
  • Application of ceritinib in preparation of medicine for treating thyroid-associated ophthalmopathy
  • Application of ceritinib in preparation of medicine for treating thyroid-associated ophthalmopathy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0031] The technical solutions of the present invention will be further described below in conjunction with the drawings and embodiments.

[0032] Ceritinib (Ceritinib) is an effective ALK inhibitor, and the invention provides a new application of Ceritinib, that is, the application of Ceritinib in the preparation of a drug for the treatment of thyroid-associated ophthalmopathy, and the symptoms of thyroid-associated ophthalmopathy include Exophthalmos, ocular soft tissue swelling, increased intraocular pressure.

[0033] Ceritinib of the present invention can be used alone when preparing the medicine for treating thyroid-associated ophthalmopathy; it can also be used in the form of pharmaceutical composition; it can also be made into pharmaceutical preparations with pharmaceutical adjuvants, such as tablets, capsules, granules, and pills , suppositories, films, gels, ointments, powders, injections, mixtures, oral liquids, syrups, liquors, sols, emulsions or eye drops, etc.

...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of ceritinib in preparation of medicine for treating thyroid-associated ophthalmopathy, and relates to the field of medicines. The pathogenesis of thyroid-related ophthalmopathy is complex, and clinical phenotypes such as eyeball protrusion and intraocular pressure increase are finally caused by adipose precursor cell differentiation enhancement in eye sockets, large-amount secretion of inflammatory factors and the like. According to the invention, lipid accumulation condition of cells subjected to complete fat induced differentiation is evaluated by virtue of Bodipy dyeing and high-content instrument analysis so as to screen drugs capable of effectively inhibiting fat differentiation and lipid accumulation. The result shows that ceritinib has an obvious inhibiting effect on fat differentiation of human orbital fibroblasts, and can inhibit expression of inflammatory factors induced by IL-17A. Thus, the treatment effect of ceritinib on thyroid-related eye diseases is verified.

Description

technical field [0001] The invention belongs to the field of medicine and relates to a new application of ceritinib, in particular to the application of ceritinib in the preparation of medicines for treating thyroid-related ophthalmopathy. Background technique [0002] Thyroid associated ophthalmopathy (TAO) is mainly caused by hyperthyroidism (hyperthyroidism, also known as Graves’ Disease, GD), an organ-specific autoimmune disease with exophthalmos as an important sign. The disease can lead to orbital deformation, double vision, and even loss of vision. As a result, Graves' ophthalmopathy has a large negative impact on patients' quality of life, mental health, and socioeconomic status. TAO has a high incidence and is the most important orbital disease. The global prevalence of GD is between 0.2-1.3%, of which about 20-30% and 5% will cause mild and moderate-severe TAO, respectively. [0003] The pathogenesis of TAO is complex and related to many factors such as genetics...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/506A61P5/16A61P27/02
CPCA61K31/506A61P5/16A61P27/02
Inventor 张芳金其煌胡敬沈宁程金伟
Owner SHANGHAI FIRST PEOPLES HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com